rhA (recombinant human albumin) is rarely mentioned these days unless someone brings it up on a CC (as I’ve done a few times). This program has fallen further and further down on the totem pole and, for all practical purposes, it might as well be considered defunct.
What happened? Perhaps there was some technical glitch that rendered the product too expensive to be suitable for the excipient market. An alternate hypothesis is that the heavy publicity about mad cow disease scared off prospective customers, who wanted no part of an albumin product that comes from cows. The writing was on the wall about this program a while ago when Fresenius declined to continue funding it.
>… the backing of, say, the Bill and Melinda Gates Foundation for the MSP-1 [malaria] vaccine while not providing a financial windfall for the company could go a long ways toward creating visibility<
Indeed it could.
News 
Market Data 
Discover 
